Journal of clinical and experimental hematopathology : JCEH最新文献

Postmarketing surveillance of brentuximab vedotin for previously untreated Hodgkin lymphoma in Japanese patients. brentuximab vedotin治疗未治疗的日本霍奇金淋巴瘤的上市后监测。

Journal of clinical and experimental hematopathology : JCEH Pub Date : 2025-06-28 Epub Date: 2025-05-30 DOI: 10.3960/jslrt.24078

Kiyoshi Okazuka, Takayuki Shimizu, Ryosuke Tawara, Masako Matsuo, Kayoko Ichihara, Koji Izutsu

{"title":"Postmarketing surveillance of brentuximab vedotin for previously untreated Hodgkin lymphoma in Japanese patients.","authors":"Kiyoshi Okazuka, Takayuki Shimizu, Ryosuke Tawara, Masako Matsuo, Kayoko Ichihara, Koji Izutsu","doi":"10.3960/jslrt.24078","DOIUrl":"10.3960/jslrt.24078","url":null,"abstract":"Febrile neutropenia (FN) poses a life-threatening risk in patients with Hodgkin lymphoma (HL) undergoing treatment with brentuximab vedotin and doxorubicin, vinblastine, and dacarbazine (A+AVD), especially in elderly patients. Although primary prophylaxis with granulocyte-colony stimulating factor (G-CSF) mitigated FN risk in ECHELON-1, limited safety data exist in Japanese patients, especially regarding neutropenia and FN after A+AVD. We assessed the real-world safety of A+AVD as first-line treatment of Japanese patients with HL. This postmarketing surveillance study collected data between November 2018 and December 2022 (study registration: JRCT1080224121; NCT03729609). Data included treatment details, response, and safety (specific focus on grade ≥3 neutropenia/FN). A total of 112 patients with previously untreated HL receiving A+AVD were included in the analysis. Overall, neutropenia incidence was 58.0%, and FN incidence was 27.7%. Two FN-related deaths occurred. Within 14 days after the first dose of A+AVD, neutropenia occurred in 26.5% and 39.7% of patients with and without early G-CSF administration (EGA), respectively, and in 27.5% and 42.6% with and without prophylactic G-CSF administration (PGA), respectively. FN occurred in 26.5% and 19.2% of patients with and without EGA, respectively, and in 17.7% and 24.6% with and without PGA, respectively. Among the 96 patients with image evaluation, excluding those whose dose was not the approved dose, 89.6% achieved a partial response or better. The real-world safety profile of A+AVD aligned with prior findings, emphasizing the importance of PGA to prevent neutropenia and FN.","PeriodicalId":520662,"journal":{"name":"Journal of clinical and experimental hematopathology : JCEH","volume":" ","pages":"84-92"},"PeriodicalIF":0.0,"publicationDate":"2025-06-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144201313","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The outcome of patients with peripheral T cell lymphoma treated with doxorubicin-based (CHOP) and pirarubicin-based regimen (THP-COP) regimen: a single institution experience. 外周血T细胞淋巴瘤患者接受基于阿霉素（CHOP）和基于比柔比星（THP-COP）方案治疗的结果：单一机构经验。

Journal of clinical and experimental hematopathology : JCEH Pub Date : 2025-06-28 Epub Date: 2025-05-30 DOI: 10.3960/jslrt.25010

Noriyoshi Iriyama, Katsuhiro Miura, Hiromichi Takahashi, Masaru Nakagawa, Kazuhide Iizuka, Shimon Otake, Takashi Hamada, Takashi Koike, Kazuya Kurihara, Toshihide Endo, Hideki Nakamura

{"title":"The outcome of patients with peripheral T cell lymphoma treated with doxorubicin-based (CHOP) and pirarubicin-based regimen (THP-COP) regimen: a single institution experience.","authors":"Noriyoshi Iriyama, Katsuhiro Miura, Hiromichi Takahashi, Masaru Nakagawa, Kazuhide Iizuka, Shimon Otake, Takashi Hamada, Takashi Koike, Kazuya Kurihara, Toshihide Endo, Hideki Nakamura","doi":"10.3960/jslrt.25010","DOIUrl":"10.3960/jslrt.25010","url":null,"abstract":"This study investigates the outcomes of patients with peripheral T-cell lymphoma (PTCL) treated with a doxorubicin-based regimen (CHOP) and a pirarubicin-based regimen (THP-COP). Newly diagnosed patients with PTCL between 2001 and 2021 were classified by initial treatment, either CHOP or THP-COP regimen. The treatment response, event-free survival (EFS), and overall survival (OS) were assessed. Overall, 65 patients were analyzed, with 41 classified into the CHOP group and 24 into the THP-COP group. Dose-intensified regimen was applied in 22 patients (53.7%) in the CHOP group and 16 (66.7%) in the THP-COP group. When stratified by treatment, the complete response (CR) rates in the CHOP group and the THP-COP group were 66% and 46% (P = 0.273), the 3-year EFS rates were 52.1% and 29.2% (P = 0.0492), and the 3-year OS rates were 72.7% and 48.6% (P = 0.0718), respectively. When stratified by treatment intensity, the CR rates in the dose-intensified group and the conventional dose group were 65% and 50% (P = 0.230), the 3-year EFS rates were 45.9% and 39.6% (P = 0.995), and the 3-year OS rates were 61.1% and 66.4% (P = 0.267), respectively. This study revealed no significant advantage of the THP-COP regimen over the CHOP regimen regarding treatment outcomes for newly diagnosed PTCLs.","PeriodicalId":520662,"journal":{"name":"Journal of clinical and experimental hematopathology : JCEH","volume":" ","pages":"93-100"},"PeriodicalIF":0.0,"publicationDate":"2025-06-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144201315","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Successful treatment of smoldering multiple myeloma-associated type I cryoglobulinemia with bortezomib and autologous peripheral blood stem cell transplantation. 硼替佐米联合自体外周血干细胞移植成功治疗阴燃型多发性骨髓瘤相关I型冷球蛋白血症

Journal of clinical and experimental hematopathology : JCEH Pub Date : 2025-06-28 Epub Date: 2025-05-30 DOI: 10.3960/jslrt.25001

Daiki Hirano, Hiroatsu Iida, Akari Iwakoshi, Akiyo Sunohara, Michita Suzuki, Yasuhiro Suzuki, Nobuhiko Imahashi, Tatsuya Adachi, Hirokazu Nagai

{"title":"Successful treatment of smoldering multiple myeloma-associated type I cryoglobulinemia with bortezomib and autologous peripheral blood stem cell transplantation.","authors":"Daiki Hirano, Hiroatsu Iida, Akari Iwakoshi, Akiyo Sunohara, Michita Suzuki, Yasuhiro Suzuki, Nobuhiko Imahashi, Tatsuya Adachi, Hirokazu Nagai","doi":"10.3960/jslrt.25001","DOIUrl":"10.3960/jslrt.25001","url":null,"abstract":"A 52-year-old male developed multiple skin ulcers/purpura in the bilateral lower limbs. A detailed examination led to a diagnosis of type I cryoglobulinemia-related skin lesions, with smoldering multiple myeloma (SMM) as a background disease. After 5 years, dermal symptoms became severe. Although there were no multiple myeloma (MM)-related symptoms other than the skin, induction therapy with bortezomib and dexamethasone (BD) was performed. Since dermal symptoms and SMM responded well to treatment, high-dose chemotherapy (melphalan) with autologous peripheral blood stem cell transplantation (ASCT) was subsequently performed. There were no serious treatment-associated adverse events. In addition, a marked response was achieved, and the disease state was stable for ≥24 months. Only a few similar case reports have been reported to date. According to a recent study, when type I cryoglobulinemia becomes symptomatic, the treatment of respective hematological diseases as a background factor and patient-matched individualized treatment should be performed. The present case suggests that it is a feasible, safe and effective treatment strategy to consider the eligibility for high-dose chemotherapy with ASCT and then perform it, even for SMM-associated type I cryoglobulinemia.","PeriodicalId":520662,"journal":{"name":"Journal of clinical and experimental hematopathology : JCEH","volume":" ","pages":"121-128"},"PeriodicalIF":0.0,"publicationDate":"2025-06-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144201314","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Increasing estrogen receptor alpha-positive follicular dendritic cells in enlarged germinal centers of IgG4-related sialadenitis. 在igg4相关涎腺炎增大的生发中心增加雌激素受体α阳性滤泡树突状细胞。

Journal of clinical and experimental hematopathology : JCEH Pub Date : 2025-06-28 Epub Date: 2025-05-30 DOI: 10.3960/jslrt.25021

Takumi Kitaoka, Rintaro Ohe

引用次数: 0

Brentuximab vedotin monotherapy for CD30-positive adult T-cell leukemia/lymphoma with HTLV-1-infected Hodgkin and Reed-Sternberg-like cells. Brentuximab vedotin单药治疗htlv -1感染霍奇金细胞和里德-斯特伯格样细胞的cd30阳性成人t细胞白血病/淋巴瘤

Journal of clinical and experimental hematopathology : JCEH Pub Date : 2025-01-01 DOI: 10.3960/jslrt.25019

Shun Ito, Hiromichi Takahashi, Haruna Watanabe-Nishimaki, Kennosuke Karube, Takahiro Namiki, Takashi Hamada, Shimon Otake, Katsuhiro Miura, Hideki Nakamura

{"title":"Brentuximab vedotin monotherapy for CD30-positive adult T-cell leukemia/lymphoma with HTLV-1-infected Hodgkin and Reed-Sternberg-like cells.","authors":"Shun Ito, Hiromichi Takahashi, Haruna Watanabe-Nishimaki, Kennosuke Karube, Takahiro Namiki, Takashi Hamada, Shimon Otake, Katsuhiro Miura, Hideki Nakamura","doi":"10.3960/jslrt.25019","DOIUrl":"https://doi.org/10.3960/jslrt.25019","url":null,"abstract":"Adult T-cell leukemia/lymphoma (ATLL) is an aggressive T-cell malignancy associated with human T-lymphotropic virus 1 (HTLV-1) infection. In this case study, we present a male patient diagnosed with CD30-positive ATLL, a rare pathological subtype characterized by the presence of HTLV-1-infected Hodgkin and Reed-Sternberg-like (HRS-like) cells. The patient was considered unsuitable for intensive chemotherapy due to advanced age and severe comorbidities. Consequently, the patient was treated with brentuximab vedotin (BV) monotherapy. Following five cycles of BV, the patient achieved partial remission (PR) without significant adverse events. Eight months have passed since the end of treatment, and the disease has not progressed. The positive results of this study suggest that BV monotherapy could be considered a viable treatment option for older or frail patients with CD30-positive ATL, particularly those with HTLV-1-infected HRS-like cells, who may not be able to tolerate standard multi-agent chemotherapy.","PeriodicalId":520662,"journal":{"name":"Journal of clinical and experimental hematopathology : JCEH","volume":"65 2","pages":"140-145"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144532822","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Monotypic versus monoclonal: Conceptual distinction in B-cell lymphoproliferative disorders. 单型与单克隆：b细胞淋巴增生性疾病的概念区别。

Journal of clinical and experimental hematopathology : JCEH Pub Date : 2025-01-01 DOI: 10.3960/jslrt.25025

Hirokazu Nakamine

引用次数: 0

Case series of long-term responders to pralatrexate in peripheral T-cell lymphoma. 外周t细胞淋巴瘤对普拉曲酯长期有效的病例系列。

Journal of clinical and experimental hematopathology : JCEH Pub Date : 2025-01-01 DOI: 10.3960/jslrt.25013

Naoto Tomita, Koichi Kitazume, Toshiki Kitajima, Hiroki Hayata, Shuku Sato, Naoya Nakamura

{"title":"Case series of long-term responders to pralatrexate in peripheral T-cell lymphoma.","authors":"Naoto Tomita, Koichi Kitazume, Toshiki Kitajima, Hiroki Hayata, Shuku Sato, Naoya Nakamura","doi":"10.3960/jslrt.25013","DOIUrl":"https://doi.org/10.3960/jslrt.25013","url":null,"abstract":"Peripheral T-cell lymphoma (PTCL) is a heterogeneous group of diseases with a tendency to relapse and poor prognosis, especially in relapsed or refractory cases. The prognosis of patients who are not eligible for autologous hematopoietic stem cell transplantation, such as older adults and those who do not respond to chemotherapy, is extremely poor. In the phase I/II study of pralatrexate in Japanese patients with relapsed or refractory PTCL, the objective response rate was 45%, the median PFS was 150 days, and long-term remission or disease maintenance was possible in approximately 20% of the patients. However, the characteristics of patients who respond to pralatrexate are unknown. Against this background, we investigated common patient characteristics in patients who achieved long-term responses to pralatrexate. Five patients were included and their characteristics were evaluated. The disease types were PTCL-not otherwise specified (NOS) in four cases and angioimmunoblastic T-cell lymphoma (AITL) in one case. The median duration of treatment with pralatrexate was 18 months (range: 7-36 months), of which 3 patients are still being treated. There were no pathological or immunohistochemical findings common to cases that responded to pralatrexate, however, of the four PTCL-NOS patients, two were GATA3 positive. Although there are limitations due to the number of cases, considering that the response rate of pralatrexate for PTCL-NOS in existing studies was 32%, these results may lead to future advances in PTCL treatment.","PeriodicalId":520662,"journal":{"name":"Journal of clinical and experimental hematopathology : JCEH","volume":"65 2","pages":"101-106"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144532823","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

RB and CHASER as induction therapy for transplant-eligible mantle cell lymphoma. RB和CHASER作为适合移植的套细胞淋巴瘤的诱导疗法。

Journal of clinical and experimental hematopathology : JCEH Pub Date : 2025-01-01 DOI: 10.3960/jslrt.25011

Toko Saito, Shigeru Kusumoto, Masamitsu Yanada, Seiichi Kato, Yoshitoyo Kagami, Yuka Kawaguchi, Hirofumi Taji, Shinya Hagiwara, Waki Hosoda, Kazuhito Yamamoto

引用次数: 0

Pemigatinib therapy in myeloid/lymphoid neoplasm with FGFR1 rearrangement manifesting as aggressive B-cell lymphoma. Pemigatinib治疗伴有FGFR1重排的骨髓/淋巴肿瘤，表现为侵袭性b细胞淋巴瘤。

Journal of clinical and experimental hematopathology : JCEH Pub Date : 2025-01-01 DOI: 10.3960/jslrt.25027

Kenichi Ito, Kazuhiko Hirano, Naohiro Sekiguchi

{"title":"Pemigatinib therapy in myeloid/lymphoid neoplasm with FGFR1 rearrangement manifesting as aggressive B-cell lymphoma.","authors":"Kenichi Ito, Kazuhiko Hirano, Naohiro Sekiguchi","doi":"10.3960/jslrt.25027","DOIUrl":"https://doi.org/10.3960/jslrt.25027","url":null,"abstract":"Myeloid/lymphoid neoplasm with FGFR1 rearrangement (MLNF) is one of the rare hematologic malignancies with variable clinical presentations, including a chronic phase resembling myeloproliferative neoplasms and an acute phase presenting as myeloid/lymphoid leukemia or lymphoma, often associated with eosinophilia. The prognosis of MLNF has been poor, and allogeneic hematopoietic stem cell transplantation (HSCT) remains the only curative approach, although selective FGFR1 inhibitors, such as pemigatinib, have recently emerged as therapeutic options. Nevertheless, the efficacy of pemigatinib in aggressive or blast-phase MLNF remains unclear. Herein, we report a case of a 67-year-old woman initially diagnosed with Richter's syndrome. The patient achieved a complete response with six cycles of rituximab-based chemoimmunotherapy followed by acalabrutinib maintenance. Two years later, the patient developed leukocytosis, eosinophilia, and recurrent lymphadenopathy. Bone marrow examination revealed disease recurrence with marked eosinophilia, and FGFR1 rearrangement was confirmed by fluorescence in situ hybridization. The rearrangement was also confirmed from the lymph node specimen of the initial diagnosis; thus, we revised the diagnosis to relapsed MLNF. The patient received pemigatinib, but rapid disease progression was observed. The patient was ineligible for HSCT and salvage chemotherapies were unsuccessful, resulting in death four months later. The present case report highlights a rare lymphoma-like clinical presentation of MLNF, and we discuss the therapeutic options, including pemigatinib.","PeriodicalId":520662,"journal":{"name":"Journal of clinical and experimental hematopathology : JCEH","volume":"65 2","pages":"146-152"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144532825","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Quantitative evaluation of treatment response to lenalidomide by applying fluorescence in situ hybridization for peripheral blood granulocytes in a patient with 5q- syndrome. 5q-综合征患者外周血粒细胞荧光原位杂交定量评价来那度胺治疗效果。

IF 1.5

Journal of clinical and experimental hematopathology : JCEH Pub Date : 2022-09-28 Epub Date: 2022-06-22 DOI: 10.3960/jslrt.22001

Hirotaka Sakai, Ikuo Miura, Ayako Arai

{"title":"Quantitative evaluation of treatment response to lenalidomide by applying fluorescence in situ hybridization for peripheral blood granulocytes in a patient with 5q- syndrome.","authors":"Hirotaka Sakai, Ikuo Miura, Ayako Arai","doi":"10.3960/jslrt.22001","DOIUrl":"https://doi.org/10.3960/jslrt.22001","url":null,"abstract":"The introduction of lenalidomide has significantly improved clinical outcomes in myelodysplastic syndrome (MDS) with isolated interstitial deletion of the long arm of chromosome 5 (del(5q)) (5q– syndrome). These days, MDS with isolated del(5q) includes cases with one additional chromosome abnormality other than monosomy 7 or del(7q), and so we need a better way to monitor tumor cells in each patient than the clinical parameters used to date. An 82-year-old woman with MDS with isolated del(5q) was treated with lenalidomide daily for 21 days in a 4-week cycle. Fluorescence in situ hybridization with CSF1R located at 5q was applied to the peripheral blood samples. Because mature lymphocytes are not involved in the MDS clone, based on the nuclear morphology, polymorphonuclear cells (PMNs) and round-shaped nuclear cells (RSNs) were separately evaluated during treatment. After a single course of treatment, the number of PMNs with del(5q) decreased; by the end of the second course of treatment, both PMNs and RSNs with del(5q) had disappeared. The dynamics of 5q– PMNs is a simple but rapid and reliable indicator to confirm the effect of lenalidomide in MDS with del(5q).","PeriodicalId":520662,"journal":{"name":"Journal of clinical and experimental hematopathology : JCEH","volume":" ","pages":"158-163"},"PeriodicalIF":1.5,"publicationDate":"2022-09-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/d1/a8/jslrt-62-158.PMC9635032.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40193356","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0